TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35867951
Drug: Lenvatinib 20
Normalized name: LENVATINIB 20MG DAILY DOSE PACK,10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib 20 mg orally once daily plus pembrolizumab 200 mg intravenously once every 3 weeks
Study: 35868533
Drug: 250 ppm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ppm inhaled carbon monoxide (CO)
Study: 35869143
Drug: First therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First therapy
Study: 35870368
Drug: Modified prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified prophylaxis regimen with alemtuzumab infusion (5 consecutive days for Course 1, 3 consecutive days for Course 2), including intravenous methylprednisolone 500mg and oral prednisone 50mg, along with oral H1 and H2 antihistaminics.
Study: 35870368
Drug: Standard prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard prophylaxis regimen with alemtuzumab infusion at Bayshore centers.
Study: 35870702
Drug: JNJ-3989 100
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-3989 100 to 400 mg Q4W
Study: 35870702
Drug: JNJ-3989 Q4W
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-3989 Q4W (200 mg) plus oral JNJ-6379 250 mg daily for 12 weeks
Study: 35870926
Drug: Grade 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grade 4 full-year mean daily school-day MVPA
Study: 35870926
Drug: Students attaining
Approvals — FDA: no, EMA: no, PMDA: no
Description: Students attaining 30+ minutes of daily school-day MVPA
Study: 35870979
Drug: Intelligent Physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intelligent Physical Exercise Training (IPET), one hour/week individualized exercise during working hours for 12 weeks, with the first 8 weeks supervised and the last 4 weeks home-administered.
Study: 35871040
Drug: Intravesical chemotherapy
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical chemotherapy (IVC) with gemcitabine
Study: 35871040
Drug: Intravesical chemotherapy
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical chemotherapy (IVC) with saline
Study: 35871310
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (rituximab, BTKi treatment)
Study: 35871310
Drug: Suboptimal responses
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suboptimal responses post-second dose
Study: 35871930
Drug: RWR therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWR therapy (liraglutide, leucine-rich amino acid infusion, hypocaloric diet)
Study: 35873000
Drug: Tofacitinib (Tofa)
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tofacitinib (Tofa) 5 mg twice a day
Study: 35873420
Drug: Infant formula
Normalized name: Infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant formula with 1.5 g/L HMOs (test group 1, TG1)
Study: 35873420
Drug: Infant formula
Normalized name: Infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant formula with 2.5 g/L HMOs (test group 2, TG2)
Study: 35873652
Drug: Salvage radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salvage radiotherapy (SRT) with 70 Gy in 35 fractions, adapted after 50 Gy, with sequential lymph node irradiation for non-responders.
Study: 35873652
Drug: PSMA-PET imaging
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSMA-PET imaging at baseline and treatment planning consideration for non-responders after 50 Gy.
Study: 35874156
Drug: Increasing Duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing Duration of rTMS treatment
Study: 35874156
Drug: Increasing Intensity
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increasing Intensity of rTMS treatment
Study: 35874156
Drug: Increasing Duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing Duration and Intensity of rTMS treatment
Study: 35874466
Drug: Neutralizing anti-Tim-3
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralizing anti-Tim-3 antibodies
Study: 35874466
Drug: Neutralizing anti-PD-1
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralizing anti-PD-1 antibodies
Study: 35874564
Drug: Norepinephrine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine at 0.2 μg/kg/min
Study: 35875816
Drug: Targeted drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted drugs based on druggable ctDNA alterations identified by next-generation sequencing (NGS)
Study: 35875816
Drug: Physician-chosen treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician-chosen treatment for patients without druggable ctDNA alterations
Study: 35876660
Drug: Hypoglycemia (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemia (blood glucose level <3.0 mmol/L)
Study: 35878676
Drug: Antidepressant drugs
Normalized name: MAO A Inhibitors, antidepressant drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant drugs (AD) treatment for 6 months
Study: 35878742
Drug: Total cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total cholesterol >220 mg/dL
Study: 35880164
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiotherapy (SBRT) regimen delivering 30 Gy in five planned consecutive daily fractions.
Study: 35880474
Drug: Control (Q1-Q3;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Q1-Q3; NT-proBNP: Q1, ≤1556 pg/mL; Q2, >1556-2816 pg/mL; Q3, >2816-5314 pg/mL)
Study: 35880941
Drug: Adoptive cell
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adoptive cell therapies
Study: 35880942
Drug: Adoptive cellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adoptive cellular therapy (ACT)
Study: 35881028
Drug: 18 mg
Normalized name: niacin 18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mg lenvatinib + everolimus (5 mg daily)
Study: 35881028
Drug: 14 mg
Normalized name: iodine 0.14 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 mg lenvatinib + everolimus (5 mg daily)
Study: 35882382
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with apparent treatment-resistant hypertension (aTRH)
Study: 35882447
Drug: CRISPR/Cas9-mediated knockout
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRISPR/Cas9-mediated knockout of TGF-β receptor 2 in OvCa TIL
Study: 35882728
Drug: PARPi-FL mouthwash
Normalized name: Paris quadrifolia extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARPi-FL mouthwash formulation (1,000 nM of PARPi-FL dissolved in 4.5 ml of PEG 300 and 9.5 ml of water)
Study: 35882728
Drug: New one-step
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: New one-step formulation of PARPi-FL (direct addition of water into a vial containing PARPi-FL and PEG 3350)
Study: 35887529
Drug: Panel of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panel of biomarkers (Neutrophil gelatinase-associated lipocalin, Kidney injury molecule-1, N-acetyl-beta-D-glucosaminidase, transferrin, ganglioside-activating protein GM2)
Study: 35887871
Drug: Ozonated water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozonated water irrigator used daily in conjunction with proper home oral hygiene.
Study: 35887871
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group performing only home oral hygiene.
Study: 35891921
Drug: Local standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local standard treatment during the 6-month control period
Study: 35893347
Drug: Sham Scrambler
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham Scrambler Therapy
Study: 35894077
Drug: Inhibitor of
Normalized name: Membrane inhibitor of reactive lysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibitor of aldose reductase (zopolrestat)
Study: 35894609
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of RAASIs and other AHAs
Study: 35894680
Drug: Referral to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral to a specific dental treatment facility
Study: 35894729
Drug: Oral Ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Ibuprofen 10 mg/kg
Study: 35894729
Drug: Oral Paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Paracetamol 10 mg/kg
Study: 35894761
Drug: Dental implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental implant treatment (four implants inserted bilaterally in the maxilla)
Study: 35894761
Drug: Dental implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental implant treatment in patients on high-dose antiresorptive medication (HDAR)
Study: 35895056
Drug: Escitalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (20 mg/d for 12 weeks)
Study: 35896216
Drug: Benralizumab 30
Normalized name: benralizumab 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab 30 mg every 8 weeks during maintenance phase
Study: 35898141
Drug: Protein-calorie supplement
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-calorie supplement
Study: 35898343
Drug: Omicron BA.1+Beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omicron BA.1+Beta (1 or 2 doses)
Study: 35900079
Drug: Magnetic Seizure
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetic Seizure Therapy
Study: 35901693
Drug: LCTOPC1 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCTOPC1 (2 × 106, 1 × 107, or 2 × 107 cells) administered via intraparenchymal injection
Study: 35902798
Drug: Total neoadjuvant
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total neoadjuvant therapy (radiotherapy: 45 Gy/25 f and concurrent chemotherapy: S-1: 40-60 mg twice a day, followed by six cycles of consolidated chemotherapy (SOX: S-1 and oxaliplatin) and surgery
Study: 35903448
Drug: n-3 PUFAs
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFAs (2.4 g/day) plus venlafaxine
Study: 35904708
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of ranibizumab (0.5 mg/0.05 ml) before vitrectomy
Study: 35904708
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of ranibizumab (0.5 mg/0.05 ml) at the end of vitrectomy
Study: 35904722
Drug: Lusutrombopag at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lusutrombopag at 3 mg for up to 7 days
Study: 35904987
Drug: AS01-adjuvanted vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS01-adjuvanted vaccine containing 120 μg of RSVPreF3
Study: 35904987
Drug: Unadjuvanted vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unadjuvanted vaccine
Study: 35905198
Drug: Albumin <
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin < 35g/L
Study: 35905224
Drug: Sevoflurane anesthesia
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane anesthesia with remifentanil followed by propofol administration
Study: 35906349
Drug: Milvexian 60
Normalized name: Milvexian
DrugBank: Milvexian (DB16233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milvexian 60 mg single oral dose
Study: 35906699
Drug: 12-week complementary
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week complementary and alternative medicine (CAM) program delivered by a therapist at a clinic; 20-session program consisting of yoga, Pilates, and dual tasking exercises.
Study: 35906699
Drug: 12-week complementary
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week complementary and alternative medicine (CAM) program initiated by the participant at home using a tablet and pre-recorded videos; 20-session program consisting of yoga, Pilates, and dual tasking exercises.
Study: 35906831
Drug: Caspofungin (empiric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin (empiric therapy)
Study: 35906831
Drug: Preemptive antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive antifungal strategy (arm B)
Study: 35906881
Drug: Anti-spike neutralizing
Normalized name: spike lavender oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-spike neutralizing monoclonal antibodies (nMoAbs)
Study: 35907135
Drug: Talazoparib (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib (1 mg/day; 0.75 mg/day for moderate renal impairment)
Study: 35907430
Drug: ChAdOx2 RabG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx2 RabG low dose (5×10^10 viral particles), n=3
Study: 35907430
Drug: ChAdOx2 RabG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx2 RabG middle dose (5×10^10 viral particles), n=3
Study: 35907430
Drug: ChAdOx2 RabG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx2 RabG high dose (5×10^10 viral particles), n=6
Study: 35907430
Drug: Follow-up after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up after 1 year for middle-dose or high-dose recipients
Study: 35907430
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a licensed rabies vaccine after ChAdOx2 RabG
Study: 35908658
Drug: Socket suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Socket suspension system
Study: 35908569
Drug: Baricitinib 4
Normalized name: baricitinib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 4 mg once daily for 10 days
Study: 35908569
Drug: JAK inhibitors
Normalized name: Janus-associated kinase (JAK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: JAK inhibitors (including baricitinib) in meta-analysis
Study: 35908569
Drug: Baricitinib or
Normalized name: baricitinib Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib or another JAK inhibitor in updated meta-analysis
Study: 35909254
Drug: Psychiatric medications
Normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychiatric medications other than benzodiazepines
Study: 35910354
Drug: 3,4-Methylenedioxymethamphetamine, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3,4-Methylenedioxymethamphetamine, dosage and duration not available
Study: 35911528
Drug: Pharmacist-managed warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-managed warfarin therapy (PMWT)
Study: 35911547
Drug: Multimodal approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal approach combining clinical, imaging, biological and electrocardiographic markers
Study: 35911547
Drug: Galectin-3 ≧
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galectin-3 ≧ 9 ng/ml
Study: 35911663
Drug: Atherectomy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atherectomy and DCB (Drug-Coated Balloon)
Study: 35911702
Drug: Induction immunochemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction immunochemotherapy (iIC) with PD-1 inhibitor plus chemotherapy every 3 weeks for at least two cycles
Study: 35911702
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (iC)
Study: 35911824
Drug: Stoss therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stoss therapy
Study: 35913656
Drug: Mean daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean daily PLGS duration between 157.5 and 174.4 min/day
Study: 35913656
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin percentage < 52.0%
Study: 35913656
Drug: Total Daily
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Daily Dose (TDD) adaptation
Study: 35914096
Drug: Vision therapy/exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vision therapy/exercises (n = 35)
Study: 35914227
Drug: Autologous stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous stem cell transplant with gene therapy (ASCT-GT)
Study: 35914239
Drug: Doxorubicin/cyclophosphamide (A/C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin/cyclophosphamide (A/C) followed by paclitaxel for neoadjuvant systemic therapy (NAST)
Study: 35914538
Drug: ReStoreD: Promoting
Approvals — FDA: no, EMA: no, PMDA: no
Description: ReStoreD: Promoting Resilience after Stroke in Dyads (8-week self-administered dyadic positive psychology intervention)
Study: 35914905
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green clearance test (IGT) administered to the donor, with a cut-off value of 13% for plasma disappearance rate (PDR).
Study: 35915019
Drug: PCSK9 levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCSK9 levels measured at baseline and after 5 days (ng/ml)
Study: 35915020
Drug: Endocrine Therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine Therapy
Study: 35915157
Drug: Panitumumab (anti-EGFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panitumumab (anti-EGFR monoclonal antibody)
Study: 35915157
Drug: Standard third-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard third-line treatments
Study: 35915419
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy (ET) initiation by 12-month interview
Study: 35915419
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy (ET) continuation for ≥12 months by 24-month interview
Study: 35915738
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with fluticasone furoate/vilanterol (FF/VI)
Study: 35915738
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with umeclidinium/vilanterol (UMEC/VI)
Study: 35916675
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of DS and LS measurements from 2D shear-wave elastography (SWE)
Study: 35916707
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of iQuit Mindfully text messages and mindfulness videoconference groups
Study: 35918666
Drug: Control period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control period with no reduction in cost for the contraceptive implant, reduced price for hormonal IUD, sliding scale for copper IUD (September 2015-March 2016)
Study: 35918703
Drug: Multi-level hypertension
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-level hypertension control program including a hypertension patient registry, performance and quality reporting, simplified treatment guidelines, access to essential medicines, team-based care, health coaching, and home blood pressure monitoring.
Study: 35918703
Drug: Control phase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control phase of sequential registration and empanelment of hypertensive patients at participating primary healthcare centers.
Study: 35918743
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (IVT-AFL) injections, mean number of injections by Month 12: 3.7 ± 1.8 (treatment-naïve), 4.0 ± 2.2 (previously treated).
Study: 35918757
Drug: Vestibular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vestibular therapy (VT) for 8 weeks, ~25-min office sessions with a vestibular therapist
Study: 35918757
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control therapy for 8 weeks
Study: 35919065
Drug: Ultra-low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low dose computed tomography (ULD-CT)
Study: 35919538
Drug: Urinary CCL14
Normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary CCL14 cutoff of 1.3 ng/ml
Study: 35919538
Drug: Urinary CCL14
Normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary CCL14 cutoff of 13 ng/ml
Study: 35919538
Drug: CCL14 concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCL14 concentration between 1.3 and 13 ng/ml
Study: 35919766
Drug: Tight Control
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight Control (TC) management with TNFi dose changes informed by biochemical markers of inflammation
Study: 35920743
Drug: elbasvir (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: elbasvir (50 mg)/grazoprevir (100 mg)
Study: 35920783
Drug: NC-6300 (Nanoparticle
Approvals — FDA: no, EMA: no, PMDA: no
Description: NC-6300 (Nanoparticle Epirubicin) at a dose of 150 mg/m2 intravenously (IV) once every 3 weeks
Study: 35921139
Drug: Secure Messaging
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Secure Messaging for Medication Reconciliation Tool (SMMRT)
Study: 35921449
Drug: L9LS administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: L9LS administered intravenously or subcutaneously at doses of 1 mg, 5 mg, or 20 mg per kilogram of body weight
Study: 35922819
Drug: SMC drugs
Normalized name: prosolv SMCC 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMC drugs only
Study: 35922819
Drug: SMC drugs
Normalized name: prosolv SMCC 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMC drugs and praziquantel